UroGen Pharma URGN Inprocess Research And Development Expense
Inprocess Research And Development Expense at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept urgn:InprocessResearchAndDevelopmentExpense.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's inprocess research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's inprocess research and development expense?
- UroGen Pharma (URGN) reported inprocess research and development expense of $0 in Q1 2026.
- How has UroGen Pharma's inprocess research and development expense changed year-over-year?
- UroGen Pharma's inprocess research and development expense decreased by 100.0% year-over-year, from $3.13M to $0.
- What does inprocess research and development expense mean?
- Represents the costs associated with research and development projects acquired in business combinations or strategic transactions that have not yet reached technological feasibility. These expenses are recognized as part of the investment in future innovation and pipeline development.